sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released a Form 8.3 concerning its position in Avadel Pharmaceuticals plc. This disclosure, submitted to the Irish Takeover Panel, pertains to relevant securities representing a significant interest, exceeding 1% of Avadel's shares.
As of November 24, 2025, Vanguard reported a holding of 5,572,254 ordinary shares in Avadel, accounting for 5.72% of the company's share capital. Additionally, they executed a purchase of 6,315 shares at $22.92 per unit. These transactions highlight Vanguard's strategic move in the pharmaceutical sector.
No cash-settled or stock-settled derivative positions were reported. Moreover, there are no current agreements, arrangements, or understandings influencing these securities or their voting rights. Vanguard has not attached any Supplemental Form 8 with this disclosure.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.